Universität zu Köln

Cappuzzo, Federico, Moro-Sibilot, Denis, Gautschi, Oliver, Boleti, Ekaterini, Felip, Enriqueta, Groen, Harry J. M., Germonpre, Paul, Meldgaard, Peter ORCID: 0000-0002-5788-4463, Arriola, Edurne ORCID: 0000-0001-8960-7519, Steele, Nicola, Fox, Jesme, Schnell, Patrick, Engelsberg, Arne and Wolf, Juergen (2015). Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. Lung Cancer, 87 (2). S. 89 - 96. CLARE: ELSEVIER IRELAND LTD. ISSN 1872-8332

Full text not available from this repository.

Abstract

Within 4 years of the discovery of anaplastic lymphoma kinase (ALK) rearrangements in non-small cell lung cancer (NSCLC), the ALK inhibitor crizotinib gained US and European approval for the treatment of advanced ALK-positive NSCLC. This was due to the striking response data observed with crizotinib in phase I and II trials in patients with ALIC-positive NSCLC, as well as the favorable tolerability and safety profile observed. Recently published phase III data established crizotinib as a new standard of care for this NSCLC molecular subset. A consequence of such rapid approval, however, is the limited clinical experience and relative paucity of information concerning optimal therapy management. In this review, we discuss the development of crizotinib and the clinical relevance of its safety profile, examining crizotinib-associated adverse events in detail and making specific management recommendations. Crizotinib-associated adverse events were mostly mild to moderate in severity in clinical studies, and appropriate monitoring and supportive therapies are considered effective in avoiding the need for dose interruption or reduction in most cases. Therapy management of patients following disease progression on crizotinib is also discussed. Based on available clinical data, it is evident that patients may have prolonged benefit from crizotinib after Response Evaluation Criteria in Solid Tumors-defined disease progression, and crizotinib should be continued for as long as the patient derives benefit. (C) 2014 The Authors. Published by Elsevier Ireland Ltd.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Cappuzzo, Federico UNSPECIFIED UNSPECIFIED UNSPECIFIED Moro-Sibilot, Denis UNSPECIFIED UNSPECIFIED UNSPECIFIED Gautschi, Oliver UNSPECIFIED UNSPECIFIED UNSPECIFIED Boleti, Ekaterini UNSPECIFIED UNSPECIFIED UNSPECIFIED Felip, Enriqueta UNSPECIFIED UNSPECIFIED UNSPECIFIED Groen, Harry J. M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Germonpre, Paul UNSPECIFIED UNSPECIFIED UNSPECIFIED Meldgaard, Peter UNSPECIFIED orcid.org/0000-0002-5788-4463 UNSPECIFIED Arriola, Edurne UNSPECIFIED orcid.org/0000-0001-8960-7519 UNSPECIFIED Steele, Nicola UNSPECIFIED UNSPECIFIED UNSPECIFIED Fox, Jesme UNSPECIFIED UNSPECIFIED UNSPECIFIED Schnell, Patrick UNSPECIFIED UNSPECIFIED UNSPECIFIED Engelsberg, Arne UNSPECIFIED UNSPECIFIED UNSPECIFIED Wolf, Juergen UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-414044
DOI:	10.1016/j.lungcan.2014.12.010
Journal or Publication Title:	Lung Cancer
Volume:	87
Number:	2
Page Range:	S. 89 - 96
Date:	2015
Publisher:	ELSEVIER IRELAND LTD
Place of Publication:	CLARE
ISSN:	1872-8332
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ANAPLASTIC LYMPHOMA; OLIGOPROGRESSIVE DISEASE; ACQUIRED-RESISTANCE; TESTOSTERONE LEVELS; CANCER-PATIENTS; C-MET; KINASE; INHIBITOR; PROGRESSION; DISCONTINUATION Multiple languages Oncology; Respiratory System Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/41404